Indaptus Therapeutics, Inc.
INDPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$19.8M | −$15.4M | −$16.4M | −$14.9M | −$7.7M | −$3.6M |
| Net income | −$20.8M | −$15.0M | −$15.4M | −$14.3M | −$7.7M | −$3.6M |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M | $1.8M |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M | $2.0M |
| Equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M | −$237,701 |
| EPS (diluted) | $-21.58 | $-44.96 | $-1.83 | $-1.73 | $-1.89 | — |
| Shares out. | 14.4M | 8.5M | 8.4M | 8.3M | 8.3M | 1.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −661.5%
- Return on assets
- −223.9%
- Return on capital (ROCE)
- −629.3%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −64.7%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 1 good- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 60,118 | 1.0 | -14.6% |
| Apr 30, 2026 | 70,403 | 1.6 | +33.9% |
| Apr 15, 2026 | 52,565 | 1.0 | +294.5% |
| Mar 31, 2026 | 13,325 | 1.0 | +54.2% |
| Mar 13, 2026 | 8,642 | 1.0 | -55.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.